Literature DB >> 10925276

Loss of IL-6 receptor expression in cervical carcinoma cells inhibits autocrine IL-6 stimulation: abrogation of constitutive monocyte chemoattractant protein-1 production.

S Hess1, H Smola, U Sandaradura De Silva, D Hadaschik, D Kube, S E Baldus, U Flucke, H Pfister.   

Abstract

IL-6 is synthesized in human papilloma virus (HPV)-transformed cervical carcinoma cell lines and is supposed to stimulate these cells in an autocrine manner. We studied IL-6 production and responsiveness in nonmalignant HPV-transformed keratinocytes and cervical carcinoma cells in detail. IL-6 was detected in cervical carcinomas in situ. Correspondingly, HPV-positive carcinoma cell lines expressed high IL-6 levels. However, these carcinoma cell lines showed low responsiveness to IL-6 as revealed by low constitutive STAT3 binding activity, which was not further enhanced by exogenous IL-6. In contrast, in vitro-transformed nonmalignant keratinocytes without endogenous IL-6 production strongly responded to exogenous IL-6 with activation of STAT3. STAT3 protein expression levels were comparable in both responsive and nonresponsive cell lines. Also, gp130, the upstream signal-transducing receptor subunit conveying IL-6 signals into the cell, was expressed in all tested cell lines. However, the IL-6 binding subunit gp80 was lost in the malignant cells. Addition of soluble gp80 was sufficient to restore IL-6 responsiveness in carcinoma cells as shown by enhanced activation of STAT3 binding activity. As a consequence of the restored IL-6 responsiveness, carcinoma cells strongly produced the chemokine monocyte chemoattractant protein-1 (MCP-1). Our data demonstrate that cervical carcinoma cells producing high amounts of IL-6 only weakly respond to IL-6 in an autocrine manner due to limited gp80 expression. While production of IL-6 might contribute to a local immunosuppressive effect, silencing an autocrine IL-6 response prevents constitutive production of the mononuclear cell-attracting chemokine MCP-1. Both mechanisms might help the tumor to escape the immune system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10925276     DOI: 10.4049/jimmunol.165.4.1939

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  A quantitative high-throughput screen for modulators of IL-6 signaling: a model for interrogating biological networks using chemical libraries.

Authors:  Ronald L Johnson; Ruili Huang; Ajit Jadhav; Noel Southall; Jennifer Wichterman; Ryan MacArthur; Menghang Xia; Kun Bi; John Printen; Christopher P Austin; James Inglese
Journal:  Mol Biosyst       Date:  2009-06-19

2.  Generation of functional monocyte-derived fast dendritic cells suitable for clinical application in the absence of interleukin-6.

Authors:  Gamal Ramadan
Journal:  Cytotechnology       Date:  2011-07-16       Impact factor: 2.058

Review 3.  Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy.

Authors:  Sigrun Smola; Connie Trimble; Peter L Stern
Journal:  Ther Adv Vaccines       Date:  2017-07-05

4.  Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells.

Authors:  Michihisa Jougasaki; Tomoko Ichiki; Yoko Takenoshita; Manabu Setoguchi
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

5.  Lipopolysaccharide-squamous cell carcinoma-monocyte interactions induce cancer-supporting factors leading to rapid STAT3 activation.

Authors:  Zoya B Kurago; Aroonwan Lam-ubol; Anton Stetsenko; Chris De La Mater; Yiyi Chen; Deborah V Dawson
Journal:  Head Neck Pathol       Date:  2008-03

6.  Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection.

Authors:  Shirish Shukla; Gauri Shishodia; Sutapa Mahata; Suresh Hedau; Arvind Pandey; Suresh Bhambhani; Swaraj Batra; Seemi F Basir; Bhudev C Das; Alok C Bharti
Journal:  Mol Cancer       Date:  2010-10-27       Impact factor: 27.401

7.  RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation.

Authors:  Susanne V Schmidt; Stefanie Seibert; Barbara Walch-Rückheim; Benjamin Vicinus; Eva-Maria Kamionka; Jennifer Pahne-Zeppenfeld; Erich-Franz Solomayer; Yoo-Jin Kim; Rainer M Bohle; Sigrun Smola
Journal:  Oncotarget       Date:  2015-04-20

8.  Cervical cancer cell supernatants induce a phenotypic switch from U937-derived macrophage-activated M1 state into M2-like suppressor phenotype with change in Toll-like receptor profile.

Authors:  Karina Sánchez-Reyes; Alejandro Bravo-Cuellar; Georgina Hernández-Flores; José Manuel Lerma-Díaz; Luis Felipe Jave-Suárez; Paulina Gómez-Lomelí; Ruth de Celis; Adriana Aguilar-Lemarroy; Jorge Ramiro Domínguez-Rodríguez; Pablo Cesar Ortiz-Lazareno
Journal:  Biomed Res Int       Date:  2014-09-21       Impact factor: 3.411

9.  RIPK3-a predictive marker for personalized immunotherapy?

Authors:  Sigrun Smola
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

Review 10.  Immunopathogenesis of HPV-Associated Cancers and Prospects for Immunotherapy.

Authors:  Sigrun Smola
Journal:  Viruses       Date:  2017-09-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.